ライフサイエンスコーパス: cyclin-dependent kinase

1 uch as Fin1 and Dam1, and phosphorylation by cyclin-dependent kinase.

2 orylation mediated by signaling pathways and cyclin-dependent kinases.

3 a) polypeptides that bind to a subset of the cyclin-dependent kinases.

4 Mxc), which is controlled by the activity of cyclin-dependent kinases.

5 ing phosphatidylinositol 3-kinase (PI3K) and cyclin-dependent kinases.

6 effect of ATR ablation is not due to altered cyclin-dependent kinase 1 (CDK1) activity, DNA damage re

7 hat YTHDF2 protein stability is dependent on cyclin-dependent kinase 1 (CDK1) activity.

8 This hyperpolarization was dependent on cyclin-dependent kinase 1 (CDK1) activity.

9 mitotic entry initiated by the activities of Cyclin-dependent kinase 1 (CDK1) and Polo-like kinase 1

10 Phosphorylation by Cyclin-dependent kinase 1 (CDK1) at two conserved sites

11 The cyclin-dependent kinase 1 (Cdk1) drives cell division.

12 l4 is phosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1) during antimitotic drug

13 We found that cyclin-dependent kinase 1 (CDK1) phosphorylated a threon

14 kinase (Aurora A)/Polo-like kinase 1 (PLK1)/cyclin-dependent kinase 1 (CDK1) signaling pathway was t

15 ence of STING led to premature activation of cyclin-dependent kinase 1 (CDK1), early onset to S-phase

16 Mitotic activation of Gwl requires both cyclin-dependent kinase 1 (CDK1)-dependent phosphorylati

17 ed in large part by a switch from mTORC1- to cyclin-dependent kinase 1 (CDK1)-mediated regulation.

18 elayed activation of Aurora A, Aurora B, and cyclin-dependent kinase 1 (CDK1).

19 at KDM5B is phosphorylated at Ser1456 by the cyclin-dependent kinase 1 (CDK1).

20 ccurs during mitosis through the activity of cyclin-dependent kinase 1 (CDK1)/cyclin B rather than th

21 Here, we identified a metabolic function of cyclin-dependent kinase 1 (CDK1)/cyclin B1-the activatio

22 osed that inhibition of the G(2)/M regulator cyclin-dependent kinase 1 decreases BMP (bone morphogene

23 inhibition with decreased phosphorylation of cyclin-dependent kinase 1 staining by immunohistochemist

24 tein kinase kinase, ribosomal S6 kinase, and cyclin-dependent kinase 1/2 in combination with Bcl-XL i

25 d) and ATR (ATM and Rad3-related) and by the cyclin-dependent kinases 1 and 2.

26 1 (MCPH1) exists as 2 isoforms that regulate cyclin-dependent kinase-1 activation and chromosome cond

27 both MCPH1 isoforms are phosphorylated in a cyclin-dependent kinase-1-dependent manner in mitosis an

28 sing iCLIP and ChIP-seq, we found that human cyclin-dependent kinase 11 (CDK11) associates with RNA a

29 Previously, we have found that cyclin-dependent kinase 11 (CDK11) signaling was essenti

30 Cyclin-dependent kinase 12 (CDK12) modulates transcripti

31 Genetic depletion of cyclin-dependent kinase 12 (CDK12) or selective inhibiti

32 Cyclin-dependent kinase 12 (CDK12) phosphorylates the ca

33 we use single-cell time-lapse microscopy of Cyclin-Dependent Kinase 2 (CDK2) activity followed by en

34 E1 (CcnE1) is the regulatory subunit of the cyclin-dependent kinase 2 (Cdk2) and controls cell cycle

35 ll lines by regulating the expression of the cyclin-dependent kinase 2 (CDK2) and cyclin D1 proteins.

36 of miR-181c significantly inhibited phospho-cyclin-dependent kinase 2 (CDK2) and cyclin-A expression

37 hase of cell cycle, elevation of Cylin E and Cyclin-dependent kinase 2 (CDK2) and downregulation of p

38 TEN) pathway reversed quiescence by inducing cyclin-dependent kinase 2 (CDK2) and reducing p21(CIP1)

39 Cyclin-dependent kinase 2 (CDK2) drives the progression

40 Cyclin-dependent kinase 2 (CDK2) is a potential therapeu

41 Cyclin-dependent kinase 2 (CDK2) is known to localize to

42 Whereas cyclin-dependent kinase 2 (Cdk2) is not necessary for mo

43 eviously, we and others report that cyclin E/cyclin-dependent kinase 2 (CDK2) phosphorylates enhancer

44 ed a specific PTPN12-insert-loop harboring a cyclin-dependent kinase 2 (CDK2) phosphorylation site.

45 Here, we show that the cell cycle regulator, cyclin-dependent kinase 2 (CDK2), couples primary beta-c

46 ssociated with Cell Division Cycle 6 (CDC6), Cyclin-dependent kinase 2 (CDK2), Cyclins D1 and D3, ind

47 Expression of the cyclin-dependent kinase 2 (CDK2), itself a downstream ta

48 E, in conjunction with its catalytic partner cyclin-dependent kinase 2 (CDK2), regulates cell cycle p

49 e elicited cell division cycle 7 (CDC7)- and cyclin-dependent kinase 2 (CDK2)-dependent reactivation

50 ptotic death of cardiomyocytes by activating cyclin-dependent kinase 2 (CDK2).

51 an alpha-helical structure, upon binding to cyclin-dependent kinase 2 (Cdk2)/cyclin A.

52 lation of TP63 expression and phosphorylated cyclin-dependent kinase 2 levels.

53 icity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating

54 The approach is illustrated by mapping cyclin-dependent kinase 2, which successfully identifies

55 Cyclin D1/D3 and cyclin-dependent kinase 2/4 (cdc2/cdc4) were downregulat

56 phosphorylation is driven by the actions of cyclin-dependent kinases 2 and 4/6 at G1/S cell-cycle ch

57 f the mammalian two-hybrid assay showed that cyclin-dependent kinase 3 (CDK3) directly interacted wit

58 Amplification of chromosome 12q13-q15 (Cyclin-dependent kinase 4 (CDK4) amplicon) is frequently

59 proinflammatory signaling pathway driven by cyclin-dependent kinase 4 (CDK4) and CDK6 and the methyl

60 ten dysregulated in malignant cells, such as cyclin-dependent kinase 4 (CDK4) and CDK6, have attracte

61 Cyclin-dependent kinase 4 (CDK4) is well-known for its r

62 Cyclin D-Cyclin-Dependent Kinase 4 (CDK4)-dependent phosphorylati

63 pproach revealed a specific interaction with cyclin-dependent kinase 4 (CDK4).

64 xpression that results in hyperactivation of cyclin-dependent kinase 4 and 6 (CDK4/6), rather than by

65 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.

66 EGFR-amplified tumours and a combination of cyclin-dependent kinase 4/6 (CDK4/6) and EGFR inhibitors

67 Many older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and an ar

68 We aimed to develop a radiolabeled cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for breas

69 Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an e

70 ls are highly sensitive to the inhibition of cyclin-dependent kinase 4/6 (CDK4/6).

71 fulvestrant is combined with palbociclib (a cyclin-dependent kinase 4/6 inhibitor), adding periodic

72 synergized with approved anti-estrogens and cyclin-dependent kinase 4/6 inhibitors (CDK4/6(i)).

73 Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are indic

74 combination of a MEK inhibitor with PI3K or cyclin-dependent kinase 4/6 inhibitors.

75 etic lethality between decreased activity of cyclin-dependent kinases 4 and 6 (CDK4/6) and VHL inacti

76 Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamenta

77 Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regula

78 We identify cyclin-dependent kinases 4 and 6 (CDK4/6) as essential r

79 Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prev

80 Cyclin-dependent kinases 4 and 6 (CDK4/6) phosphorylate

81 on with HER2-targeted therapy, inhibitors of cyclin-dependent kinases 4 and 6, angiogenesis inhibitor

82 phosphatidylinositol-3 kinase (PI3K) and/or cyclin-dependent kinases 4/6 (CDK4/6).

83 ent studies suggest that deregulation of p25/Cyclin-dependent kinase 5 (Cdk5) activity leads to the h

84 action content decreases after inhibition of cyclin-dependent kinase 5 (Cdk5) and ERK1/2.

85 Furthermore, Cadm4, cyclin-dependent kinase 5 (Cdk5) and p39 mRNAs were sign

86 Here we investigate the inhibition of cyclin-dependent kinase 5 (Cdk5) as a promising combinat

87 Cyclin-dependent kinase 5 (Cdk5) has been involved in pr

88 t of MAPKs and proline-directed kinases like cyclin-dependent kinase 5 (Cdk5) in cell-based as well a

89 odynia and upregulates Ca(V)3.2 channels and cyclin-dependent kinase 5 (Cdk5) in dorsal root ganglia

90 We recently identified an essential role for cyclin-dependent kinase 5 (Cdk5) in T-cell activation an

91 Here, we report for the first time that cyclin-dependent kinase 5 (Cdk5) is an essential regulat

92 Cyclin-dependent kinase 5 (CDK5) is known to underlie bo

93 the algorithm, we showed that inhibition of Cyclin-dependent kinase 5 (Cdk5) led to reduced branchin

94 ulatory cell signals for CAP1, we found that cyclin-dependent kinase 5 (CDK5) phosphorylates both Ser

95 Here, we show that the cyclin-dependent kinase 5 (CDK5) regulates the mammalian

96 Here, we show that cyclin-dependent kinase 5 (Cdk5), a protein kinase that

97 The cyclin-dependent kinase 5 (CDK5), originally described a

98 Cyclin-dependent kinase 5 (Cdk5), which binds to and is

99 p35, is known to induce aberrant activity of cyclin-dependent kinase 5 (Cdk5), which is associated wi

100 t Ser(424) and Ser(429) in the C terminus by cyclin-dependent kinase 5 (Cdk5).

101 purmorphamine treatment was shown to reduce cyclin-dependent kinase 5 in patient cells, suggesting a

102 of both glycogen synthetase kinase 3beta and cyclin-dependent kinase 5 is required to prevent P301L-i

103 of both glycogen synthetase kinase 3beta and cyclin-dependent kinase 5 prevents tau mislocalization t

104 using roscovitine and siRNA directed towards cyclin-dependent kinase 5) ameliorated the cilia phenoty

105 ermore, 7j is highly effective in preventing cyclin-dependent kinase 5-mediated phosphorylation of PP

106 , leads to tau phosphorylation by activating cyclin-dependent kinase 5.

107 STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and MycNol3(-/-) MPN Th

108 downregulation of its proven targets, namely cyclin-dependent kinase 6 and Mcl1.

109 ribe a novel treatment strategy that targets cyclin-dependent kinase 7 (CDK7) in HER2 inhibitor-resis

110 nt findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke an

111 Cyclin-dependent kinase 7 (CDK7) is a central regulator

112 Cyclin-dependent kinase 7 (CDK7) is the catalytic subuni

113 clib blocks glucose consumption by targeting cyclin-dependent kinase 7 (CDK7) similar to other CDK7 i

114 Cyclin-dependent kinase 7 (CDK7), Cyclin H, and the RING

115 al machinery and especially to inhibition of cyclin-dependent kinase 7 (CDK7), which is essential for

116 particular, to THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7).

117 subunit kinase module, which contains either cyclin-dependent kinase 8 (CDK8) or CDK19.

118 inase module that includes the MED13, MED12, cyclin-dependent kinase 8 (CDK8), and cyclin C (CCNC) su

119 The activity of its catalytic core, cyclin-dependent kinase 8 (CDK8), is controlled by Cycli

120 -specific process: a new replication factor, cyclin-dependent kinase 8/19-cyclinC (Cdk8/19-cyclin C),

121 We identify cyclin dependent kinase 9 (CDK9) as a novel binding part

122 We found that SIRT2 deacetylates cyclin-dependent kinase 9 (CDK9) in a type I IFN-depende

123 Cyclin-dependent kinase 9 (CDK9) is a novel prognostic m

124 phosphorylation of elongation factor Spt5 by cyclin-dependent kinase 9 (Cdk9) occur during transcript

125 Mechanistically, BRD4 is required for cyclin-dependent kinase 9 (CDK9) recruitment and phospho

126 s 9 (H3K9ac) and 56 (H3K56ac), activation of cyclin-dependent kinase 9 (CDK9)-that phosphorylates NEL

127 omain containing 4 (BRD4) with NF-kappaB and cyclin-dependent kinase 9 (CDK9).

128 Inhibition of both cyclin-dependent kinase 9 activity and viral DNA replica

129 FF4-CHD as a substrate for the P-TEFb kinase cyclin-dependent kinase 9, which triggers release of pol

130 horylated at an N-terminal serine cluster by cyclin-dependent kinase-9 (CDK9), which is recruited int

131 disruption of the core cell cycle regulator CYCLIN-DEPENDENT KINASE A;1 (CDKA;1) and that this repre

132 canonical two-step mechanism in which 1) the cyclin-dependent kinase activating kinase Cak1 phosphory

133 lar eukaryote Saccharomyces cerevisiae, Cln3-cyclin-dependent kinase activity enables Start, the irre

134 e of eukaryotes and, despite lacking obvious cyclin-dependent kinase and cyclin homologs, has an orde

135 rary identified kenpaullone, an inhibitor of cyclin-dependent kinases and glycogen synthase kinase 3,

136 Cyclins, cyclin-dependent kinases and other components of the cor

137 d that regulators of the G(1) phase, such as cyclin-dependent kinases and pRb (retinoblastoma protein

138 fs targeted by the kinases protein kinase C, cyclin-dependent kinase, and mitogen-activated protein k

139 reduced upregulation of p21, an inhibitor of cyclin-dependent kinases, and blocked G1 arrest after TB

140 nclude the epidermal growth factor receptor, cyclin-dependent kinases, and heat shock protein 90.

141 Cyclin-dependent kinases are therapeutic targets frequen

142 ts and how they led to the identification of cyclin-dependent kinases as core to these cell cycle con

143 s precise synchronisation of the activity of cyclin dependent kinases at distinct stages of the cell

144 Here, we demonstrate that the cyclin-dependent kinase CDK-1 primes the recruitment of

145 The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for hor

146 lation of the retinoblastoma (RB) protein by cyclin-dependent kinase (CDK) 4/6 and increased G1-S pro

147 ion and represents the downstream target for cyclin-dependent kinase (CDK) 4/6 inhibitors that are in

148 ide (analog 24), which selectively inhibited cyclin-dependent kinase (CDK) 5 over CDK2 in cancer cell

149 Cyclin-dependent kinase (CDK) 7 has a unique functional

150 tivating kinase (CAK), a complex composed of cyclin-dependent kinase (CDK) 7, cyclin H, and MAT1, is

151 Although cyclin-dependent kinase (CDK) 9 has an established patho

152 with Ku70 to promote NHEJ in G1 when overall cyclin-dependent kinase (CDK) activity is low.

153 tosis is ordered by thresholds of increasing cyclin-dependent kinase (Cdk) activity.

154 ty is further required to promote loading of cyclin-dependent kinase (CDK) and proliferating cell nuc

155 hanism demonstrated for other substrates, as cyclin-dependent kinase (CDK) binding-defective mutants

156 s (p21(Cip1) /p27(Kip1) ) inhibit cyclin and cyclin-dependent kinase (CDK) complex that promotes fibr

157 /kip1 (p27) tumor suppressor inhibits cyclin/cyclin-dependent kinase (CDK) complexes and halts cell c

158 Cyclin D-CDK4/6 are the first cyclin-dependent kinase (CDK) complexes to be activated

159 T387 lies in a cyclin-dependent kinase (CDK) consensus sequence, and CD

160 N1 stabilizes and increases the level of the cyclin-dependent kinase (CDK) inhibitor p27, which inhib

161 Arabidopsis (Arabidopsis thaliana) encodes a cyclin-dependent kinase (CDK) inhibitor that plays a cen

162 an cancer cell lines(3-5), we identify CR8-a cyclin-dependent kinase (CDK) inhibitor(6)-as a compound

163 and, mTOR inhibition blunts the induction of cyclin-dependent kinase (CDK) inhibitors (CDKIs), includ

164 tagal) activity, increased expression of the cyclin-dependent kinase (CDK) inhibitors p16INK4A (CDKN2

165 l gene in chordoma, and that transcriptional cyclin-dependent kinase (CDK) inhibitors targeting CDK7/

166 Since cyclin-dependent kinase (CDK) inhibitors, CDKN2A and CDK

167 growth-arrested because of the expression of cyclin-dependent kinase (CDK) inhibitors.

168 migration and development independent of its cyclin-dependent kinase (CDK) inhibitory action.

169 ation in host cells because the HCMV-encoded cyclin-dependent kinase (CDK) ortholog pUL97 extensively

170 encement of anaphase, is mediated by mitotic cyclin-dependent kinase (CDK) phosphorylation of the GTP

171 Here, we adapt a cyclin-dependent kinase (CDK) sensor to uncouple these k

172 ies on multisite phosphorylation networks of cyclin-dependent kinase (CDK) targets have opened a new

173 hich the master regulator of the cell cycle, cyclin-dependent kinase (CDK), temporally coordinates an

174 1's activation loop is phosphorylated by the cyclin-dependent kinase (CDK)-activating kinase (Cak1),

175 process that is controlled by the conserved cyclin-dependent kinase (CDK)-cyclin protein complex(1).

176 e we demonstrate that Ngn3 protein undergoes cyclin-dependent kinase (Cdk)-mediated phosphorylation o

177 The cyclin-dependent kinase (CDK)-RB-E2F axis forms the core

178 110 to counterbalance its phosphorylation by cyclin-dependent kinase (Cdk).

179 the spindle pathway and under the control of cyclin-dependent kinase (CDK).

180 cally disordered protein (IDP) that inhibits cyclin-dependent kinase (Cdk)/cyclin complexes (e.g., Cd

181 Cyclin-dependent kinase (CDK)/cyclin complexes drive mos

182 Here, we described that the complex Clb2-cyclin-dependent kinase (Cdk)1, one of the master regula

183 Cyclin-dependent kinase (CDK)6 is a member of the CDK fa

184 of Serine 118 (Ser118) by the TFIIH kinase, cyclin-dependent kinase (CDK)7.

185 Brd4 and cyclin-dependent kinases (CDK) had critical regulatory r

186 cells were highly sensitive to inhibitors of cyclin-dependent kinases (CDK), especially THZ1, a coval

187 requires a decisive shift in the balance of cyclin-dependent kinase Cdk1 and PP2A:B55 activity.

188 the protein kinase Wee1, which inhibits the cyclin-dependent kinase Cdk1 in yeast through human cell

189 uted to bistability in the activation of the cyclin-dependent kinase Cdk1.

190 ylation in yeast Hsp70 (Ssa1) is promoted by cyclin-dependent kinase (Cdk1) during normal growth.

191 Phosphorylation of Sae2 by cyclin-dependent kinase (CDK1/Cdc28) activates the Mre11

192 nthesized using a bioinformatics strategy as cyclin-dependent kinases CDK2 and CDK9 inhibitors, which

193 le arrest when bound in ternary complex with cyclin-dependent kinase (Cdk2) and cyclins (e.g., Cdk2/C

194 We demonstrate that cyclin-dependent kinase (CDK2) can bind to the promoters

195 Further, we show that CNTD1 interacts with a cyclin-dependent kinase, CDK2, which also accumulates in

196 re found in most human cancers, and specific cyclin-dependent kinase Cdk4/6 inhibitors are approved o

197 eactivate the RB pathway using inhibitors of cyclin-dependent kinases CDK4 and CDK6 are effective in

198 In-depth transcriptomic analysis identifies cyclin-dependent kinases CDK4 and CDK6 as regulators of

199 The cyclin-dependent kinases Cdk4 and Cdk6 form complexes wi

200 Although the cyclin-dependent kinases CDK4 and CDK6 play fundamental

201 py; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially imp

202 cyclins (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components

203 Cyclin C-cyclin-dependent kinase (Cdk8) is a component of the RNA

204 Phaeodactylum tricornutum, by binding to two cyclin-dependent kinases, CDKA1 and CDKA2.

205 nding factor TRF2 within the promoter of the cyclin-dependent kinase CDKNIA (p21/CIP1/WAF1).

206 Furthermore, proper levels of cyclin dependent kinases (CDKs) and cyclins, including D

207 The cyclin-dependent kinases (CDKs) 12 and 13 phosphorylate

208 ng confirmed high selectivity of 4.35 toward cyclin-dependent kinases (CDKs) 2, 5, and 9, and the coc

209 ammals is strictly controlled by a number of cyclin-dependent kinases (CDKs) and CDK inhibitors (CKIs

210 ylation of hundreds of different proteins by cyclin-dependent kinases (CDKs) and other kinases.

211 cle (Cdc) kinase subunit (CKS) proteins bind cyclin-dependent kinases (CDKs) and play important roles

212 tes is controlled by the conserved family of cyclin-dependent kinases (CDKs) and their partner cyclin

213 govern eukaryotic cell cycle progression are cyclin-dependent kinases (CDKs) and their partners.

214 Cyclin-dependent kinases (CDKs) are frequently deregulat

215 Cyclins and cyclin-dependent kinases (CDKs) are hyperactivated in nu

216 Increasing evidence suggests that cyclin-dependent kinases (Cdks) are inappropriately acti

217 Cyclin-dependent kinases (Cdks) are principal drivers of

218 The cyclin-dependent kinases (CDKs) are the major cell-cycle

219 tributor of PAH pathobiology, and identified cyclin-dependent kinases (CDKs) as overactivated kinases

220 ly triggered by variation in the activity of cyclin-dependent kinases (CDKs) bound to cyclins.

221 ivision, cyclin-specific docking motifs help cyclin-dependent kinases (CDKs) phosphorylate different

222 Furthermore, we show that cyclin-dependent kinases (CDKs) phosphorylate PAH1 at se

223 Cyclin-dependent kinases (CDKs) regulate cell cycle prog

224 kinase signaling, restricts the activity of cyclin-dependent kinases (CDKs) that promote cell divisi

225 f cell cycle progression in conjunction with cyclin-dependent kinases (CDKs).

226 oliferation and acts primarily by inhibiting cyclin-dependent kinases (CDKs).

227 sis induced two cellular responses involving cyclin-dependent kinases (CDKs).

228 pecific cyclins that act in association with cyclin-dependent kinases (CDKs).

229 cket protein-E2F binding specificity and how cyclin-dependent kinases differentially regulate pocket

230 C-terminal domain that is phosphorylated by cyclin-dependent kinases during the transition from init

231 Trypanosoma brucei CRK9 is an essential cyclin-dependent kinase for the parasite-specific mode o

232 The Arabidopsis (Arabidopsis thaliana) cyclin-dependent kinase G1 (CDKG1) is necessary for reco

233 gene, dicer, and a probable uncharacterized cyclin dependent kinase in honey bees, we utilized RNAi

234 Sex-dependent associations involve cyclin-dependent kinases in bladder cancer, the MAPK sig

235 gehog (Shh) pathway agonist purmorphamine or cyclin-dependent kinase inhibition (using roscovitine an

236 unrecognized convergence of Shh agonism and cyclin-dependent kinase inhibition as potential therapeu

237 genes phosphatase and tensin homolog (PTEN), cyclin dependent kinase inhibitor 2A (CDKN2A), LKB1, and

238 identifying the well-known tumor suppressor cyclin dependent kinase inhibitor 2A (Cdkn2a), whose alt

239 his study, we show that dinaciclib, a potent cyclin dependent kinase inhibitor, significantly increas

240 These include the cyclin-dependent kinase inhibitor (CDKI) p18INK4c, the m

241 g a model of resistance to a pharmacological cyclin-dependent kinase inhibitor (CDKi), we show that t

242 e, we show that polymersomes can deliver the cyclin-dependent kinase inhibitor (R)-roscovitine into h

243 In the absence of Jdp2, a complex of the cyclin-dependent kinase inhibitor 1 (p21(Cip1)) and Nrf2

244 phase, and induces expression of p(21CIP1) (cyclin-dependent kinase inhibitor 1), and p(27KIP1) (cyc

245 The BRCA2 DNA repair associated (BRCA2) and cyclin-dependent kinase inhibitor 1A (CDKN1A) interactin

246 Expression levels of the Cyclin-dependent kinase inhibitor 1a (CDKN1A), Growth/di

247 ed by short-term NEUROG3 expression required cyclin-dependent kinase inhibitor 1A (CDKN1A)/p21(CIP1)

248 ecies and p38 MAPK-dependent upregulation of cyclin-dependent kinase inhibitor 1A (Cdkn1a, encoding f

249 l-cycle genes, and we identified the mRNA of cyclin-dependent kinase inhibitor 1A (Cdkn1a, p21) as a

250 echanism was identified as downregulation of cyclin-dependent kinase inhibitor 1B (p27(Kip1)) via upr

251 ependent kinase inhibitor 1), and p(27KIP1) (cyclin-dependent kinase inhibitor 1B) expression, key ce

252 sistent microbial insult (e.g. LPSs) induces cyclin-dependent kinase inhibitor 2A (CDKN2A/p16(INK4a))

253 essor genes RB1 (retinoblastoma) and CDKN2a (cyclin-dependent kinase inhibitor 2a) are critical cell-

254 Increased expression of CDKN2A (cyclin-dependent kinase inhibitor 2A)-a downstream targe

255 tion and 3-fold hypomethylation of the human cyclin-dependent kinase inhibitor 2B (CDKN2B or p15) gen

256 ociated with reduced levels of the p21(Cip1) cyclin-dependent kinase inhibitor and tumor suppressor p

257 mediates GC formation through repression of cyclin-dependent kinase inhibitor CDKN1A (p21(Cip1)).

258 Both SCF complexes targeted the cyclin-dependent kinase inhibitor Cdkn1b for polyubiquit

259 Hairy and Enhancer of Split 1 (HES1) and the cyclin-dependent kinase inhibitor CDKN1C/p57 as novel ta

260 Here, we show that the cyclin-dependent kinase inhibitor Dacapo (Dap; ortholog

261 Using the cyclin-dependent kinase inhibitor dinaciclib, which down

262 We have found that the expression of p21, a cyclin-dependent kinase inhibitor involved in cell cycle

263 was reported to control the stability of the CYCLIN-DEPENDENT KINASE inhibitor KIP-RELATED PROTEIN (K

264 l cycle regulators cyclins D, A2, and B2 and cyclin-dependent kinase inhibitor p20 in brain tissue.

265 rrest accompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expr

266 The cyclin-dependent kinase inhibitor p21 is an important pl

267 an increase in the tumor protein p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1, which ar

268 ell proliferation and elevated expression of cyclin-dependent kinase inhibitor P27 (P27KIP1) in a GEF

269 re, attributed to elevated expression of the cyclin-dependent kinase inhibitor p27, a Siah2 substrate

270 osol, which causes hyper-accumulation of the cyclin-dependent kinase inhibitor p27, leading to mitoti

271 regulation of c-Myc and stabilization of the cyclin-dependent kinase inhibitor p27/KIP1.

272 The cyclin-dependent kinase inhibitor p57(kip2) is encoded b

273 We confirmed that AT7159 (cyclin-dependent kinase inhibitor), AT9283, (Janus kinas

274 specific upregulation of p57Kip2, a Cip/Kip cyclin-dependent kinase inhibitor, and we identified thi

275 eased expression of PDGFRbeta and p57kip2, a cyclin-dependent kinase inhibitor, in these cells.

276 Specifically, encapsulation of dinaciclib, a cyclin-dependent kinase inhibitor, into PD-L1-targeted L

277 r senescence by repressing the expression of cyclin-dependent kinase inhibitor, p21(Waf1/Cip1).

278 lation of the Skp2-degradation target p27, a cyclin-dependent kinase inhibitor, which was confirmed a

279 inary efforts have led to the development of Cyclin-Dependent Kinase inhibitors (CDKi's) as small mol

280 of the cell cycle, decreasing expression of cyclin-dependent kinase inhibitors and upregulating pro-

281 mechanisms, including YAP/TAZ signaling and cyclin-dependent kinase inhibitors, by blocking entry in

282 Cyclin-dependent kinase-like 5 (CDKL5) deficiency is a n

283 d learning and memory.SIGNIFICANCE STATEMENT Cyclin-dependent kinase-like 5 (CDKL5) deficiency is a s

284 disorder caused by mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene.

285 Pathogenic mutations in cyclin-dependent kinase-like 5 (CDKL5) result in CDKL5 d

286 Cyclin-dependent kinase-like 5 disorder is a severe neur

287 orates deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder', by Gao etal.

288 le binding, which is negatively regulated by Cyclin-dependent kinase-mediated phosphorylation of segm

289 uggest that combined inhibition of RAF and d-cyclin-dependent kinases might provide an effective appr

290 In this study, we show that in yeast, the cyclin-dependent kinase Pho85/CDK5 provides protection a

291 We find that protein kinase C and cyclin-dependent kinase phosphorylate ANG, enabling ANG

292 The second pathway involves cyclin-dependent kinase phosphorylation of Cdc20, which

293 Cyclin-dependent kinases play multiple roles in RNA poly

294 novo missense variants in CDK19, encoding a cyclin-dependent kinase protein family member that predo

295 sates and that phosphorylation by regulatory cyclin-dependent kinases reduces this incorporation.

296 Loss of the adaptor protein cyclin-dependent kinase regulatory subunit 1 (Cks1), a c

297 NUCKS1 (nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate 1) is a chromatin-asso

298 nally selected for cell fitness, enriched in Cyclin-dependent kinase substrates, and evolutionarily c

299 eport that Magnaporthe oryzae CKS1 encodes a cyclin-dependent kinase subunit, which plays a significa

300 e human cytomegalovirus (HCMV)-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates the